Sansure Biotech Inc. develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. Its product portfolio includes nucleic acid diagnostic kits for infectious diseases such as coronavirus, influenza, and HPV, as well as extraction and PCR instruments. The company also engages in drug research and production, raw material procurement, electronic equipment manufacturing, and provides third-party medical testing and biotechnology services. Founded in 2008, it is headquartered in Changsha, China.
Sansure Biotech's 2026 interim report shows net profit down 39.76%
Sansure Biotech released its 2026 interim report. Total operating revenue was 834 million yuan, down 3.95% from the same period last year. Net profit attributable to the parent company was 98.02 million yuan, down 39.76% year on year. Net cash flow from operating activities was negative 15.66 million yuan, ranking 78th among disclosed peer companies. The company's latest asset-liability ratio was 26.59%, gross margin was 71.32%, return on equity was 1.40%, and diluted earnings per share was 0.17 yuan. The company had 20,900 shareholders, and the top ten shareholders held 298 million shares, accounting for 51.41% of total share capital.
Sansure Biotech Plans Cash Dividend of 2.65 Yuan per 10 Shares
Sansure Biotech announced on August 26 that it plans to distribute a cash dividend of 2.65 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 151 million yuan. In the first half of 2026, the company achieved revenue of 834 million yuan and net profit attributable to the parent of 98.02 million yuan.
Sansure Biotech first-half net profit falls 39.76% year on year; plans dividend of 2.65 yuan per 10 shares
Sansure Biotech disclosed its interim report on August 26. In the first half of 2026, it achieved operating revenue of 834 million yuan, down 3.95% year on year. Net profit attributable to shareholders of the listed company was 98.0173 million yuan, down 39.76% year on year. Basic earnings per share were 0.17 yuan. The company plans to distribute a cash dividend of 2.65 yuan, tax included, for every 10 shares. During the reporting period, reagent sales were affected by price declines driven by centralized procurement, medical insurance cost controls, and payment method reforms. The growth hormone products of its subsidiary Zhongshan Haiji were affected by expanded medical insurance coverage and product price cuts. In addition, the value-added tax rate on self-produced testing reagent products in the in vitro diagnostics industry was raised from 3% to 13%, which had a significant impact on profit. Furthermore, the company increased strategic investment in instruments, research and development innovation, and industrial mergers and acquisitions integration. The related increase in investment diluted profit in the short term.
Sansure Biotech first-half net profit attributable to parent was 98.02 million yuan, down 39.8% year on year
Sansure Biotech released its 2026 interim report. First-half net profit attributable to the parent was 98.02 million yuan, down 39.8% year on year, while operating revenue was 834 million yuan, down 3.9% year on year. Second-quarter operating revenue was 397 million yuan, up 1.0% year on year, but net profit attributable to the parent was 48.28 million yuan, down 32.0% year on year. The company said that centralized procurement, medical insurance cost controls and payment reform led to lower reagent prices. The growth hormone products of its subsidiary Zhongshan Haiji were also affected by expanded medical insurance coverage and price cuts. At the same time, the value-added tax rate on self-produced testing reagents in the in vitro diagnostics industry was raised from 3% to 13%, which had a significant impact on profit. The company is increasing investment in instruments, research and development innovation, and industrial mergers and acquisitions, and sticking to its integrated diagnosis and treatment strategy to cope with short-term profit dilution.
Sansure Biotech's combined dengue and chikungunya nucleic acid test approved for market
Sansure Biotech announced that its dengue virus and chikungunya virus nucleic acid detection kit recently received a medical device registration certificate from the National Medical Products Administration. The product is the first domestically approved combined nucleic acid test for dengue and chikungunya to enter the market.
Former 5% shareholder Chen Wenyi of Sansure Biotech faces judicial enforcement of 5.71 million shares
Sansure Biotech announced that a portion of shares held by former shareholder Chen Wenyi, who previously held more than 5%, is subject to judicial enforcement. The Zhuzhou Intermediate People's Court in Hunan Province plans to sell a total of 5.71 million unrestricted tradable shares held by Chen through block trades or centralized bidding in batches, representing 0.99% of the company's total share capital, with the reduction period no later than December 30, 2027. After this enforcement, Chen's shareholding will decrease from 26.4274 million shares to 20.7174 million shares, and his stake will drop from 4.56% to 3.58%. This matter will not affect the stability of the company's control and will not impact daily operations.
Sansure Biotech shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares
Sansure Biotech announced that shareholder Chen Wenyi's 5.71 million shares, representing 0.99% of the company's total share capital, are subject to judicial enforcement. The enforcement stems from debt repayment obligations of Chen Wenyi and entities under his control to the creditor applicant. The court will permit the applicant to sell the shares in batches through block trades or centralized bidding on the secondary market, with the reduction period no later than December 30, 2027. In the first quarter of 2026, Sansure Biotech achieved revenue of 437 million yuan and net profit attributable to the parent company of 49.74 million yuan.
Sansure Biotech Secures EU CE IVDR Certification for Five Products
Sansure Biotech announced that it has recently obtained EU CE IVDR certification for five products, including a human papillomavirus nucleic acid typing test kit, a combined SARS-CoV-2 and influenza virus test kit, and HIV, HBV, and HCV nucleic acid test kits. Among them, the HIV, HBV, and HCV nucleic acid test kits are the first to receive the highest-risk Class D certification, further enriching the company's respiratory, maternal and child, and blood-borne disease testing product lines and supporting its internationalization strategy.
Sansure Biotech's First Freeze-Dried Nucleic Acid Test for Respiratory Infections Approved
Sansure Biotech disclosed that its nucleic acid test kit for the novel coronavirus, influenza A virus, influenza B virus, and respiratory syncytial virus recently obtained a Medical Device Registration Certificate from the National Medical Products Administration. This product is Sansure Biotech's first approved freeze-dried nucleic acid test for respiratory infections, and also the first reagent developed based on AI protein evolution enzyme technology, capable of simultaneously detecting four common high-incidence pathogens. The reagent is compatible with Sansure Biotech's molecular point-of-care testing devices, completing the entire process from sample loading to result output in as fast as 12 minutes, and is also compatible with conventional PCR testing platforms, meeting the testing needs of various settings such as emergency departments, primary care, and central laboratories.
Sansure Biotech's Group A Streptococcus Nucleic Acid Detection Kit Receives Medical Device Registration Certificate
Sansure Biotech announced that its Group A Streptococcus Nucleic Acid Detection Kit (Fluorescent PCR Method) has recently obtained a Medical Device Registration Certificate from the National Medical Products Administration. The kit is used for in vitro qualitative detection of Group A Streptococcus nucleic acid in human throat swab samples. It can be combined with the company's rapid nucleic acid detection solution for respiratory infections to achieve simultaneous multi-pathogen detection, helping to improve early diagnosis efficiency and standardize antimicrobial use.
Multiple A-share Companies Announce Buybacks and Stake Increases; Neusoft Plans Buyback with Full Cancellation
On the evening of July 9, multiple A-share listed companies issued announcements on share buybacks and stake increases. Neusoft announced that, because its stock price is below net asset value per share, it plans to buy back shares worth 100 million to 200 million yuan and cancel them all. Based on a maximum buyback price of 11.67 yuan per share, the number of shares to be repurchased is approximately 8.57 million to 17.14 million, accounting for 0.72% to 1.43% of total share capital. Yibai Pharmaceutical will cancel 7.53 million repurchased shares, representing 0.95% of total share capital, after which total share capital will change to 784 million shares. Unigroup Guoxin will cancel 6.40 million shares because the repurchased shares were not used for an incentive plan within 36 months. Sansure Biotech will cancel 4.45 million shares to reduce registered capital, aiming to boost earnings per share. Chongqing Pharmaceutical has completed the cancellation procedures for 15.41 million repurchased shares. Dazhong Mining made its first buyback of 580,000 shares, with a transaction amount of 17.51 million yuan. Jiayi Holdings made its first buyback of 64,200 shares, with a transaction amount of 1.99 million yuan. Qingmu Technology plans to buy back shares worth 20 million to 30 million yuan for incentive purposes. On the stake increase side, Sheng Jianhua, one of the actual controllers of Xidian New Energy, increased his stake by 614,900 shares, with an amount of 19.45 million yuan. Actual controllers Sheng Jianhua and Pan Shuxin plan to increase their combined stake by 10 million to 20 million yuan. The controlling shareholder of Shenghang Shipping, Wanda Holding Group, plans to increase its stake by no more than 6.10 million shares, with an amount of 66 million to 96 million yuan. Liu Xiaodong, the actual controller of Bairun Holdings, increased his stake by 1.12 million shares, with an amount of 17.98 million yuan, and plans to continue increasing his stake by 50 million to 100 million yuan. Some directors and senior executives of Longxi Bearing increased their combined stake by 67,400 shares, with an amount of 909,400 yuan.
China